FC
RXRX icon

Farringdon Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Farringdon Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,582
Closed -$66.6K – 575
2025
Q1 		$66.6K Buy
+12,582
New +$91.7K 0.03% 305

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Farringdon Capital's RXRX Position: Q2 2025 in Review

Farringdon Capital sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 12,582 shares — an estimated $66.6K sold.

Farringdon Capital first reported a position in RXRX in Q1 2025 and held it in 1 quarter. The position peaked at $66.6K in Q1 2025. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Farringdon Capital reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Farringdon Capital sold 12,582 Recursion Pharmaceuticals shares in Q2 2025, an estimated $66.6K.
  • Farringdon Capital first reported a position in Recursion Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Farringdon Capital's Recursion Pharmaceuticals position peaked at $66.6K in Q1 2025.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Farringdon Capital's 13F filing for Q2 2025, filed 14 Aug 2025.